Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
Pyridoxamine (PM) is a promising drug candidate for treatment of diabetic nephropathy. The therapeutic effect of PM has been demonstrated in multiple animal models of diabetes and in phase II clinical trials. However, the mechanism of PM therapeutic action is poorly understood. One potential mechanism is scavenging of pathogenic reactive carbonyl species (RCS) found to be elevated in diabetes. We have suggested previously that the pathogenicity of RCS methylglyoxal (MGO) may be due to modification of critical arginine residues in matrix proteins and interference with renal cell-matrix interactions. We have also shown that this MGO effect can be inhibited by PM (Pedchenko et al. (2005) Diabetes 54, 2952-2960). These findings raised the questions of whether the effect is specific to MGO, whether other structurally different physiological RCS can act via the same mechanism, and whether their action is amenable to PM protection. In the present study, we have shown that the important physiological RCS 3-deoxyglucosone (3-DG) can damage protein functionality, including the ability of collagen IV to interact with glomerular mesangial cells. We have also demonstrated that PM can protect against 3-DG-induced protein damage via a novel mechanism that includes transient adduction of 3-DG by PM followed by irreversible PM-mediated oxidative cleavage of 3-DG. Our results suggest that, in diabetic nephropathy, the therapeutic effect of PM is achieved, in part, via protection of renal cell-matrix interactions from damage by a variety of RCS. Our data emphasize the potential importance of the contribution by 3-DG, along with other more reactive RCS, to this pathogenic mechanism.
Chetyrkin
Sergei V
SV
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
Zhang
Wenhui
W
Hudson
Billy G
BG
Serianni
Anthony S
AS
Voziyan
Paul A
PA
D000818:Animals; D002417:Cattle; D002448:Cell Adhesion / Q000187:drug effects; D002461:Cell Line, Transformed; D024141:Collagen Type IV / Q000737:chemistry; D003847:Deoxyglucose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D003928:Diabetic Nephropathies / Q000188:drug therapy; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D050527:Mesangial Cells / Q000166:cytology; D051379:Mice; D011733:Pyridoxamine / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D012259:Ribonuclease, Pancreatic / Q000737:chemistry; D021241:Spectrometry, Mass, Electrospray Ionization; D013400:Sugar Acids / Q000032:analysis / Q000737:chemistry
D024141:Collagen Type IV; D013400:Sugar Acids; C060458:3-deoxyglucose; D011733:Pyridoxamine; D003847:Deoxyglucose; D012259:Ribonuclease, Pancreatic